AACR Annual Meeting 2025, Chicago, IL, April 25-30
Conference
genOway presentation

genOway’s program at the American Association for Cancer Research Annual Meeting 2025
🔬 Spotlight Theater presentation
Tuesday, April 29, 2025 | 3 pm - Spotlight Theater E
Title: "Assessment of translational tumor biology, and biologic's efficacy and safety in preclinical humanized models"
Presenter: Kader Thiam, CSO & SVP – Discovery, Preclinical Models & Services
Presentation highlights:
- genO-BRGSF-HIS mouse is a tool to assess the efficacy and safety of immunotherapies targeting lymphoid and myeloid cellsgenO-BRGSF-HIS mouse
- TME in genO-BRGSF-HIS mice is shaped by tumor type and tumor burden
- genO-hFcγR model represents an alternative to genO-BRGSF-HIS to evaluate compounds working through Fc-mediated functions
📰 Poster presentations
⮞ Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice | Download poster here
- Human CD47 and SIRPα expression patterns recapitulate the murine expression of CD47 and SIRPα in genO-hCD47/hSIRPα model
- Efficacy and safety of CD47- and/or SIRPα-targeting agents can be assessed in the genO-hCD47/hSIRPα model
- genO-hCD47/hSIRPα model is suitable for biodistribution assay for non-invasive in vivo imaging of tumors
⮞ Preclinical double-humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies | Download poster here
- genO-BRGSF-HIS mouse is permissive to cell line xenograft engraftment
- TME composition and cell polarization evolve with tumor burden and depend on tumor type in genO-BRGSF-HIS mouse
- genO-BRGSF-HIS mouse model is a valuable tool to investigate mechanism of action of immunotherapies
⮞ Functional γδ T cells in genO-BRGSF-HIS mice | Download poster here
- γδ T cells develop in genO-BRGSF-HIS mice and can be expanded ex vivo and in vivo using Vγ9 expanders
- γδ T cells are recruited into the TME of tumor-bearing genO-BRGSF-HIS mice
- genO-BRGSF-HIS model brings a new perspective to evaluate therapies designed to expand and activate γδ T cells
⮞ genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies | Download poster here
- Humanization of both CCR8 and CCL1 is required for a functional axis and does not alter immune cell distribution in genO-hCCR8/hCCL1 compared to WT mice
- CCR8-targeting therapies can be assessed in genO-hCCR8/hCCL1 model
- Human-like expression pattern of CCR8 in genO-BRGSF-HIS naïve Tregs makes it a more suitable model for safety and PD assessment
AACR Annual Meeting 2025, Chicago, IL, April 25-30
Get in touch
Other news & events
Scientific excellence
From model design to experimental results
Tailor-made solutions adapted to scientific questionsRobust validation data on catalog models
Comprehensive dataset package
Generated with biopharma partners and in-houseCustomer care
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative modelsEasy and fast access to models
Breeding facilities in US and Europe
Certified health status from professional breeders